Patents by Inventor Demetri T. Moustakas
Demetri T. Moustakas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11780845Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.Type: GrantFiled: January 31, 2023Date of Patent: October 10, 2023Assignees: Relay Therapeutics, Inc., D.E. Shaw Research, LLCInventors: Bakary-Barry Touré, Heike Schoenherr, Fabrizio Giordanetto, Demetri T. Moustakas, Brandi M. Hudson
-
Publication number: 20230192709Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.Type: ApplicationFiled: January 31, 2023Publication date: June 22, 2023Inventors: Bakary-Barry TOURÉ, Heike SCHOENHERR, Fabrizio GIORDANETTO, Demetri T. MOUSTAKAS, Bradi M. DUDSON
-
Publication number: 20230104574Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.Type: ApplicationFiled: May 12, 2020Publication date: April 6, 2023Inventors: Bakary-Barry TOURÉ, Heike SCHOENHERR, Alexander M. TAYLOR, Fabrizio GIORDANETTO, Demetri T. MOUSTAKAS, Thomas H. MCLEAN, Brandi M. HUDSON, Mary M. MADER, Pelin AYAZ, Dina A. SHARON, Ravi KURUKULASURIYA, Alessandro BOEZIO
-
Patent number: 11534480Abstract: The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: (first monomer subunit)-LINKER-(second monomer subunit)?? Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.Type: GrantFiled: May 16, 2019Date of Patent: December 27, 2022Assignee: ALKERMES, INC.Inventors: Demetri T. Moustakas, Mark N. Namchuk, Heather C. Losey, Juan C. Alvarez
-
Publication number: 20210177983Abstract: The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.Type: ApplicationFiled: November 30, 2020Publication date: June 17, 2021Inventors: Juan Alvarez, Demetri T. Moustakas, Heather R. Brodkin, Leslie A. McSweeney
-
Patent number: 10881741Abstract: The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.Type: GrantFiled: April 10, 2018Date of Patent: January 5, 2021Assignee: Alkermes, Inc.Inventors: Juan Alvarez, Demetri T. Moustakas, Heather R. Brodkin, Leslie A. McSweeney
-
Patent number: 10807995Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.Type: GrantFiled: July 11, 2019Date of Patent: October 20, 2020Assignee: Alkermes Pharma Ireland LimitedInventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
-
Patent number: 10799496Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.Type: GrantFiled: July 11, 2019Date of Patent: October 13, 2020Assignee: Alkermes Pharma Ireland LimitedInventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
-
Publication number: 20200016151Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.Type: ApplicationFiled: July 11, 2019Publication date: January 16, 2020Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
-
Publication number: 20200017529Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.Type: ApplicationFiled: July 11, 2019Publication date: January 16, 2020Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
-
Publication number: 20190336582Abstract: The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: (first monomer subunit)-LINKER-(second monomer subunit)?? Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.Type: ApplicationFiled: May 16, 2019Publication date: November 7, 2019Inventors: Demetri T. Moustakas, Mark N. Namchuk, Heather C. Losey, Juan C. Alvarez
-
Patent number: 10335459Abstract: The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: (first monomer subunit)-LINKER-(second monomer subunit)?? Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.Type: GrantFiled: June 22, 2017Date of Patent: July 2, 2019Assignee: Alkermes, Inc.Inventors: Demetri T. Moustakas, Mark N. Namchuk, Heather C. Losey, Juan C. Alvarez
-
Publication number: 20180289825Abstract: The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.Type: ApplicationFiled: April 10, 2018Publication date: October 11, 2018Inventors: Juan Alvarez, Demetri T. Moustakas, Heather R. Brodkin, Leslie A. McSweeney
-
Publication number: 20170368144Abstract: The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: (first monomer subunit)-LINKER-(second monomer subunit)?? Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.Type: ApplicationFiled: June 22, 2017Publication date: December 28, 2017Inventors: Demetri T. Moustakas, Mark N. Namchuk, Heather C. Losey, Juan C. Alvarez
-
Publication number: 20160175458Abstract: The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.Type: ApplicationFiled: December 18, 2015Publication date: June 23, 2016Inventors: Juan Alvarez, Demetri T. Moustakas, Heather R. Brodkin, Leslie A. McSweeney
-
Publication number: 20080113421Abstract: The present invention generally relates to enzymes and other proteins resistant to denaturation, and techniques for making and using the same. In one aspect, lysine and/or other charged residues within an enzyme are reacted in some fashion, which can render the enzyme more resistant to denaturation. For example, the lysine residue may be neutralized by acetylating the residue, for instance, by exposure to acetic anhydride. In some aspects, the enzyme, after reaction, may be relatively resistant to degradation when placed in a harsh environment, for example, when exposed to sodium dodecyl sulfate at a concentration of at least about 2.5 mM in Tris-Gly buffer. The enzyme may still be susceptible to denaturation in some cases, but at a much slower rate (e.g., the denaturation time constant may be higher). Other aspects of the invention are directed to enzymes prepared in such fashion, methods of promoting or using such enzymes, kits involving such enzymes, and the like.Type: ApplicationFiled: December 11, 2006Publication date: May 15, 2008Applicant: President and Fellows of Harvard CollegeInventors: Bryan F. Shaw, Katherine L. Gudiksen, Irina Gitlin, Demetri T. Moustakas, George M. Whitesides